5. Culturally Competent Care for Substance Users Diagnosed with HIV Disease
Treatment of Mental Disorders in HIV-Infected Patients
With the continuing intersecting epidemics of HIV disease and substance abuse, the need both to understand and to learn to manage the potential interactions among the medications used to treat each condition will continue to grow. Knowing that there are risks for such interactions may prevent some clinicians or patients from wanting to initiate potentially life-saving therapy. However, awareness that substance users who are receiving effective substance use therapy are likely to be more adherent to and experience better clinical outcomes with HAART should empower patients and providers alike to move forward with carefully integrated treatment for both conditions. With injection drug use being both a risk factor for HIV infection and treatment of substance use being a potential complication of antiretroviral therapy, the most extensively evaluated drug-drug interactions involve those between antiretrovirals and the opioid agonists methadone and buprenorphine.
Methadone and buprenorphine. A number of antiretroviral agents can decrease or increase methadone levels, and clinicians should monitor patients for signs and symptoms of methadone withdrawal or toxicity when initiating or discontinuing HAART. On the other hand, most antiretrovirals, including those that alter buprenorphine levels, do not cause buprenorphine withdrawal or toxicity. However, co-administered atazanavir/ritonavir is an exception and is associated with significant increases in buprenorphine levels and, in some patients, adverse events such as sedation and changes in mental status. For both methadone or buprenorphine, potential interactions with some of the newer antiretrovirals—as well as some of the drugs used to treat complications of HIV infection—have not yet been well studied. [Gruber 2010]
Because the potential interactions between antiretrovirals and methadone or buprenorphine are so wide-ranging and can require such a variety of dose adjustments, clinicians who are managing patients requiring both HAART and opioid agonist treatment should consult one of the regularly updated databases of antiretroviral interactions with all types of drugs:
- One developed by the Center for HIV Information at the University of California, San Francisco: http://hivinsite.ucsf.edu/insite?page=ar-00-02
- The other maintained by the Liverpool HIV Pharmacology Group at the University of Liverpool: http://www.hiv-druginteractions.org/
Interactions between antiretrovirals and other substance abuse treatment medications are much less wide-ranging than those with methadone and buprenorphine.
Naltrexone. Although earlier studies indicated potential interaction between zidovudine and naltrexone—used to assist patients who have discontinued drinking alcohol and using street drugs in avoiding further use of alcohol or drugs—no zidovudine toxicity has been reported when the drug is co-administered with naltrexone. [McCance-Katz 2001]
Acamprosate. Antiretroviral interactions with acamprosate—used to assist patients who have discontinued drinking alcohol in avoiding further alcohol consumption—primarily involve oral solutions of the protease inhibitor ritonavir (including the liquid formulation of lopinavir/ritonavir) and the oral solution of the protease inhibitor amprenavir, as these agents contain alcohol and propylene glycol, respectively.
Disulfiram. Antiretroviral interactions with disulfiram—used to treat alcoholism by causing unpleasant symptoms when alcohol is consumed—primarily involve oral solutions of the protease inhibitor ritonavir (including the liquid formulation of lopinavir/ritonavir) and the oral solution of the protease inhibitor amprenavir, as these agents contain alcohol and propylene glycol, respectively. Disulfiram should not be co-administered with these agents.
Information concerning interactions between each of these substance abuse treatments and antiretroviral agents—as well as information about numerous other drug-drug interactions with antiretrovirals—can be found at either of the 2 databases mentioned above.